WO2025228315 - ANTI-N3PGLU AMYLOID BETA ANTIBODIES AND USES THEREOF
National phase entry is expected:
Publication Number
WO/2025/228315
Publication Date
06.11.2025
International Application No.
PCT/CN2025/091621
International Filing Date
28.04.2025
Title **
[English]
ANTI-N3PGLU AMYLOID BETA ANTIBODIES AND USES THEREOF
[French]
ANTICORPS ANTI-BÊTA-AMYLOÏDES N3PGLU ET LEURS UTILISATIONS
Applicants **
JACOBIO PHARMACEUTICALS CO., LTD.
Inventors
LIU, Fangjie
LI, Shuang
WANG, Yanping
Priority Data
PCT/CN2024/090253
28.04.2024
CN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
CNIPA
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2634 | |
| EPO | Filing, Examination, Granting | 26508 | |
| Japan | Filing, Examination, Granting | 3055 | |
| South Korea | Filing, Examination, Granting | 3923 | |
| USA | Filing, Examination, Granting | 12340 |
Total:
48,460
Contact Us
Abstract[English]
Provided are antibodies that selectively bind N3pGlu Amyloid Beta peptide and their use in treating conditions or diseases characterized by deposition of Amyloid Beta.[French]
L'invention concerne des anticorps qui se lient sélectivement au peptide bêta-amyloïde N3pGlu et leur utilisation dans le traitement d'états ou de maladies caractérisés par le dépôt de bêta-amyloïdes.